#health systems #Switzerland #Novo Nordisk #Geneva #WHO Foundation

Strengthening Global Health Systems: The Collaboration of WHO Foundation and Novo Nordisk

In a significant development for public health, the WHO Foundation has announced an enhanced collaboration with pharmaceutical giant Novo Nordisk. This partnership aims to provide crucial financial support to strengthen health systems dealing with the increasing burden of cardio-renal and metabolic diseases, including obesity and diabetes. The initiative is positioned as a global response to one of the most pressing health challenges of our time.

Financial Commitment

Novo Nordisk has committed a total of $7.9 million to this effort. This includes an initial donation of $2.9 million set to be released in 2024, followed by an additional $5 million aimed at supporting initiatives in December 2025. Such substantial financial backing is expected to significantly bolster the efforts of the WHO Foundation and its health partners to combat non-communicable diseases, particularly in low- and middle-income countries.

Addressing Public Health Challenges

Anil Soni, the Director General of the WHO Foundation, emphasized the complexity of cardio-renal and metabolic diseases, highlighting the need for prevention-focused approaches grounded in robust health systems. He stated, "By supporting the WHO in its preventive role, we can enhance the scientific and public health foundations that countries need to respond effectively and equitably to these challenges."

Elin Jäger, the Senior Vice President of Business Strategy and Sustainability at Novo Nordisk, echoed this sentiment, stressing the importance of broad-scale partnerships. She stated, "The fight against obesity, diabetes, and related conditions requires collaboration among governments, communities, civil society, and the private sector to advance prevention, early screening, and care. By increasing Novo Nordisk's contribution to the WHO Foundation, we hope more countries will have the tools, data, and resources needed to take effective local action."

Global Context of Obesity

The urgency of this collaboration is underscored by alarming global statistics. Over one billion individuals worldwide are affected by obesity—comprising approximately 650 million adults, 340 million adolescents, and 39 million children. Since 1975, the prevalence of obesity has nearly tripled, leading to more deaths globally than underweight conditions. Currently, 39 million children under the age of five are classified as overweight or obese, with over 340 million adolescents aged 5 to 19 facing similar challenges. These statistics highlight that combating obesity is not only a matter of physical health but a multi-faceted issue that encompasses various societal factors.

Role of the WHO Foundation

Established in 2020 and based in Geneva, the WHO Foundation operates independently to support the mission of the World Health Organization. It mobilizes philanthropic funds and creates catalytic partnerships to advance health equity and address urgent health challenges while strengthening life-saving systems. By facilitating connections between stakeholders and practitioners, the Foundation aims to develop reliable solutions, finance life-saving responses, and foster sustainable health improvements for all.

Conclusion

The collaboration between the WHO Foundation and Novo Nordisk marks a pivotal step towards addressing global health challenges posed by cardio-renal and metabolic diseases. With substantial financial support and a focus on collaboration among various sectors, this partnership aims to equip countries with essential tools and resources to combat the growing incidence of obesity and associated health issues effectively. As the world grapples with these pressing health concerns, such collaborations will be critical in forging pathways to healthier societies.